MMAPPP Act of 2020

Bill: 116-hr-7296
Sponsor: Rep. Schakowsky, Janice D. [D-IL-9]
Introduced: 2020-06-22 in the House
Policy area: Health
Subjects: Business records
Cardiovascular and respiratory health
Civil actions and liability
Corporate finance and management
Drug safety, medical device, and laboratory regulation
Emergency medical services and trauma care
Government information and archives
Health programs administration and funding
Health promotion and preventive care
Immunology and vaccination
Infectious and parasitic diseases
Inflation and prices
Intellectual property
Licensing and registrations
Manufacturing
Medical research
Medical tests and diagnostic methods
Performance measurement
Prescription drugs
Research administration and funding
Research and development
User charges and fees
Wages and earnings

Summary:
action_date: 2020-06-22
text: 

Make Medications Affordable by Preventing Pandemic Price gouging Act of 2020 or the MMAPPP Act of 2020

 
This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies.
 
With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill. 
 
The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access. 
 
If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.


Legislative actions:
action_date: 2020-06-22
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2020-06-22
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2020-06-22
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2020-06-22
text: Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
action_date: 2020-06-22
text: Introduced in House
action_date: 2020-06-22
text: Introduced in House